Stocks in play: PharmaTher Inc
Is pleased to provide an update on the Company’s psilocybin pharmaceutical development programs. The Company is evaluating psilocybin as a potential treatment for methamphetamine use disorder with the University of Wisconsin-Madison through a clinical trial agreement. PharmaTher Inc shares C.PHRM are trading unchanged at $0.34.
Read:
New Treatments Needed as Breast Cancer Was Leading Killer of Female Cancer Patients in 2019
Biotech Sector Answering Calls for New Breast Cancer Treatment Developments in 2022
Alternative Domestic Supplies of Critical Minerals Needed to Facilitate Energy Transition
Flexitarians Driving Food Manufacturers to Double-Down on Plant-Based Proteins
Drug Developers Gaining Positive Results in Fight Against Blood Cancers